Newsletter | June 17, 2026

06.17.26 -- Five Reasons The Hub-And-Spoke Model Is Gaining Traction In Biotech

FEATURED ARTICLE

Five Reasons The Hub-And-Spoke Model Is Gaining Traction In Biotech

Biotech is adopting hub-and-spoke models to share resources, reduce asset risk, and scale innovation. This approach improves efficiency, supports agile teams, and builds repeatable systems for advancing pipelines in a competitive, cost-constrained R&D environment.

INDUSTRY INSIGHTS

Redefining eSource: A Smarter, Site-Centric Approach To Clinical Trial Data Capture

Discover how AI-powered extraction and site-centric workflows improve data quality and reduce administrative burdens for research teams.

Patient Trust And Engagement In The Age Of Decentralized Trials

To truly maximize enrollment in decentralized models, sponsors must invest in human connection to build the trust needed to move patients from awareness to active participation.

Click To Randomization: Better Patient Qualification In Psych Trials

How can you, as a sponsor, optimize recruitment workflows, enhance patient screening, and ensure sites receive higher-quality patients?

How To Reduce Patient Dropout Rates In Clinical Trials

Sponsors are addressing patient dropout rates by shifting from reactive troubleshooting to proactive protocol designs that minimize participant burden.

How To Best Navigate The Global Clinical Trial Registry Ecosystem

This presentation is your GPS, guiding you on a path that includes harmonization initiatives intended to improve transparency and data consistency across registries.

Streamlining Biologics Development With Small-Scale Studies

Uncover how a data-driven approach to small-scale studies not only accelerates development timelines but also enhances decision-making and resolves full-scale manufacturing challenges across diverse biologic modalities.

Setting A New Standard For Biotech Program Visibility

An on‑demand session showing how integrated governance and real‑time data boost visibility, collaboration, and control in outsourced gene therapy development.

Connect With Life Science Leader: